-1 |BT| (S1 (S (NP (NN Granulosa) (NNS cells)) (VP (VBD were) (VP (VP (VBN isolated) (PP (IN from) (NP (JJ bovine) (JJ preovulatory) (NNS follicles)))) (CC and) (VP (VBN cultured) (PP (IN for) (NP (NP (CD 3) (NNS days)) (PP (IN with) (CC or) (PP (IN without) (NP (NN _PROT1_)))))) (PP (IN in) (NP (NP (NP (NP (NN medium)) (VP (VBN supplemented) (PP (IN with) (NP (CC either) (NP (NP (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (CD 1) (NN microgram/ml)) (-RRB- -RRB-))) (CC +) (NP (ADJP (CD 1) (NN %)) (NP (NP (JJ fetal) (NN calf) (NN serum)) (PRN (-LRB- -LRB-) (NP (NN FCS)) (-RRB- -RRB-))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ maintains) (NP (JJ basal) (NN estradiol) (NN secretion))))) (, ,)) (CC or) (NP (NP (JJ low) (NNS doses)) (PP (IN of) (NP (NP (NN FSH)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CC and) (CD 2)) (NN ng/ml)) (-RRB- -RRB-))))))))) (CC +) (NP (ADJP (CD 1) (NN %)) (NN FCS))) (, ,) (NP (NP (DT a) (NN culture) (NN condition)) (SBAR (WHNP (WDT that)) (S (VP (VBZ maximizes) (NP (NP (NNS effects)) (PP (IN of) (NP (NN FSH))) (PP (IN on) (NP (NN estradiol) (NN secretion))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NN Wortmannin)) (VP (VBZ converts) (NP (NP (NN _PROT1_)) (CONJP (CC but) (RB not)) (NP (NN _PROT2_))) (PP (IN from) (NP (DT an) (JJ antilipolytic))) (PP (TO to) (NP (NP (DT a) (JJ lipolytic) (NN agent)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NN forskolin)))))))))) |ET|
-1 |BT| (S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (VBD compared) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN in) (NP (NN rat) (NNS adipocytes)))) (PP (IN with) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN _PROT2_)) (CC and) (NP (NN peroxovanadate)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP mimic) (NP (NP (DT some) (NNS effects)) (PP (IN of) (NP (NN _PROT_)))))))))) |ET|
-1 |BT| (S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (VBD compared) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN _PROT1_))) (PP (IN in) (NP (NN rat) (NNS adipocytes)))) (PP (IN with) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN peroxovanadate)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP mimic) (NP (NP (DT some) (NNS effects)) (PP (IN of) (NP (NN _PROT2_)))))))))) |ET|
-1 |BT| (S1 (S (NP (DT The) (JJ present) (NNS studies)) (VP (VBD compared) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN _PROT_))) (PP (IN in) (NP (NN rat) (NNS adipocytes)))) (PP (IN with) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN peroxovanadate)))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP mimic) (NP (NP (DT some) (NNS effects)) (PP (IN of) (NP (NN _PROT2_)))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT The) (JJ antilipolytic) (NNS effects)) (PP (IN of) (NP (NP (NN peroxovanadate)) (CC and) (NP (NN _PROT1_))))) (VP (VBD were) (VP (VBN unaffected) (PP (IN by) (NP (ADJP (CD 500) (NN nmol/L)) (NN wortmannin)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD blocked) (NP (NP (DT the) (JJ antilipolytic) (NN action)) (PP (IN of) (NP (NN _PROT2_)))))))))) |ET|
-1 |BT| (S1 (S (NP (DT The) (NNS data)) (VP (VBP provide) (NP (NP (JJ additional) (NN support)) (PP (IN for) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (NP (NN _PROT1_)) (CC and) (NP (NN peroxovanadate))) (VP (VBP affect) (NP (NN adipose) (NN tissue) (NN metabolism)) (PP (IN by) (NP (NP (NNS mechanisms)) (ADJP (RB distinctly) (JJ different) (PP (IN from) (NP (NP (DT those)) (VP (VBN involved) (PP (IN in) (NP (NN _PROT2_) (NN action)))))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT This) (NN effect)) (VP (VP (VBZ is) (ADJP (JJ maximal) (PP (IN at) (NP (NP (CD 10) (-LRB- -LRB-) (CD -8) (-RRB- -RRB-) (NN M)) (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN concentration)) (PP (ADVP (RB clearly)) (IN above) (NP (NP (DT the) (JJ normal) (JJ physiological) (NN range)) (PP (IN of) (NP (NN _PROT1_) (NNS concentrations)))))) (-RRB- -RRB-))))))) (CC and) (VP (VBZ involves) (NP (DT the) (NN V2) (NN receptor) (NN pathway)) (, ,) (SBAR (IN while) (S (NP (NP (NP (NN activation)) (PP (IN of) (NP (NN _PROT_) (NN _PROT_) (NN _PROT_)))) (CC or) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ intracellular) (NN calcium))))) (VP (VBP are) (NP (JJ ineffective))))))))) |ET|
-1 |BT| (S1 (S (NP (DT This) (NN effect)) (VP (VP (VBZ is) (ADJP (JJ maximal) (PP (IN at) (NP (NP (CD 10) (-LRB- -LRB-) (CD -8) (-RRB- -RRB-) (NN M)) (NP (NP (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN concentration)) (PP (ADVP (RB clearly)) (IN above) (NP (NP (DT the) (JJ normal) (JJ physiological) (NN range)) (PP (IN of) (NP (NN _PROT1_) (NNS concentrations)))))) (-RRB- -RRB-))))))) (CC and) (VP (VBZ involves) (NP (DT the) (NN V2) (NN receptor) (NN pathway)) (, ,) (SBAR (IN while) (S (NP (NP (NP (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)))) (CC or) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ intracellular) (NN calcium))))) (VP (VBP are) (NP (JJ ineffective))))))))) |ET|
-1 |BT| (S1 (S (NP (DT This) (NN effect)) (VP (VP (VBZ is) (ADJP (JJ maximal) (PP (IN at) (NP (NP (CD 10) (-LRB- -LRB-) (CD -8) (-RRB- -RRB-) (NN M)) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN concentration)) (PP (ADVP (RB clearly)) (IN above) (NP (NP (DT the) (JJ normal) (JJ physiological) (NN range)) (PP (IN of) (NP (NN _PROT_) (NNS concentrations)))))) (-RRB- -RRB-))))))) (CC and) (VP (VBZ involves) (NP (DT the) (NN V2) (NN receptor) (NN pathway)) (, ,) (SBAR (IN while) (S (NP (NP (NP (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)))) (CC or) (NP (NP (NNS changes)) (PP (IN in) (NP (JJ intracellular) (NN calcium))))) (VP (VBP are) (NP (JJ ineffective))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN Activation)) (PP (IN of) (NP (NN EGFR) (VBG overexpressing) (NN 3T3-L1) (NNS adipocytes)))) (VP (VBZ leads) (PP (TO to) (NP (NP (NP (DT a) (ADJP (ADJP (CD 3.4)) (CC +/-) (ADJP (JJ 1.2-fold))) (NN stimulation)) (PP (IN of) (NP (NP (NN _PROT1_) (NN activity)) (PP (IN over) (NP (JJ basal) (NNS levels)))))) (CC vs.) (NP (NP (QP (RB only) (CD 1.06) (CC +/-) (CD 0.01-fold)) (NN stimulation)) (PP (IN by) (NP (NN _PROT2_))))))) (. .))) |ET|
+1 |BT| (S1 (S (PP (IN Despite) (NP (NP (DT the) (JJ low) (NNS levels)) (PP (IN of) (NP (JJ _PROT1_) (NN _PROT2_) (NN activity))))) (, ,) (NP (JJ _PROT_) (NN glucose) (NN transport) (NN activity)) (VP (VBD was) (ADVP (RB similarly)) (VP (VBN inhibited) (PP (IN by) (NP (NP (NN U73122)) (PRN (-LRB- -LRB-) (NP (QP (CD 55.9) (CC +/-) (CD 13.1)) (NN %) (NN inhibition)) (-RRB- -RRB-)))))))) |ET|
-1 |BT| (S1 (S (PP (IN Despite) (NP (NP (DT the) (JJ low) (NNS levels)) (PP (IN of) (NP (JJ _PROT1_) (NN _PROT_) (NN activity))))) (, ,) (NP (JJ _PROT2_) (NN glucose) (NN transport) (NN activity)) (VP (VBD was) (ADVP (RB similarly)) (VP (VBN inhibited) (PP (IN by) (NP (NP (NN U73122)) (PRN (-LRB- -LRB-) (NP (QP (CD 55.9) (CC +/-) (CD 13.1)) (NN %) (NN inhibition)) (-RRB- -RRB-)))))))) |ET|
-1 |BT| (S1 (S (PP (IN Despite) (NP (NP (DT the) (JJ low) (NNS levels)) (PP (IN of) (NP (JJ _PROT_) (NN _PROT1_) (NN activity))))) (, ,) (NP (JJ _PROT2_) (NN glucose) (NN transport) (NN activity)) (VP (VBD was) (ADVP (RB similarly)) (VP (VBN inhibited) (PP (IN by) (NP (NP (NN U73122)) (PRN (-LRB- -LRB-) (NP (QP (CD 55.9) (CC +/-) (CD 13.1)) (NN %) (NN inhibition)) (-RRB- -RRB-)))))))) |ET|
-1 |BT| (S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN _PROT1_) (NN activation)))) (VP (VBD did) (RB not) (VP (VB impair) (NP (CC either) (NP (NP (NP (NN EGF-)) (CC or) (NP (JJ _PROT2_) (NN activation))) (PP (IN of) (NP (NN glycogen) (NN synthase)))) (CC or) (NP (NP (NN incorporation)) (PP (IN of) (NP (NN glucose))) (PP (IN into) (NP (NN lipid))))) (, ,) (S (VP (VBG supporting) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (CC both) (NP (NN EGF-)) (CC and) (NP (JJ _PROT_) (NN glucose) (NN disposal))) (VP (MD can) (VP (VB be) (ADJP (JJ independent) (PP (IN of) (NP (JJ GLUT4-mediated) (NN glucose) (NN transport)))))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN _PROT1_) (NN activation)))) (VP (VBD did) (RB not) (VP (VB impair) (NP (CC either) (NP (NP (NP (NN EGF-)) (CC or) (NP (JJ _PROT_) (NN activation))) (PP (IN of) (NP (NN glycogen) (NN synthase)))) (CC or) (NP (NP (NN incorporation)) (PP (IN of) (NP (NN glucose))) (PP (IN into) (NP (NN lipid))))) (, ,) (S (VP (VBG supporting) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (CC both) (NP (NN EGF-)) (CC and) (NP (JJ _PROT2_) (NN glucose) (NN disposal))) (VP (MD can) (VP (VB be) (ADJP (JJ independent) (PP (IN of) (NP (JJ GLUT4-mediated) (NN glucose) (NN transport)))))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NN _PROT_) (NN activation)))) (VP (VBD did) (RB not) (VP (VB impair) (NP (CC either) (NP (NP (NP (NN EGF-)) (CC or) (NP (JJ _PROT1_) (NN activation))) (PP (IN of) (NP (NN glycogen) (NN synthase)))) (CC or) (NP (NP (NN incorporation)) (PP (IN of) (NP (NN glucose))) (PP (IN into) (NP (NN lipid))))) (, ,) (S (VP (VBG supporting) (NP (DT the) (NN hypothesis) (SBAR (IN that) (S (NP (CC both) (NP (NN EGF-)) (CC and) (NP (JJ _PROT2_) (NN glucose) (NN disposal))) (VP (MD can) (VP (VB be) (ADJP (JJ independent) (PP (IN of) (NP (JJ GLUT4-mediated) (NN glucose) (NN transport)))))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (NP (NP (DT The) (NN diminution)) (PP (IN of) (NP (NP (NN glucose) (NN transport)) (ADJP (JJ secondary) (PP (TO to) (NP (NP (NN inhibition)) (PP (IN of) (NP (NN _PROT1_) (NN activity))))))))) (VP (VBD was) (VP (VBN reflected) (PP (IN by) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN GLUT4) (NN translocation)) (PP (TO to) (NP (DT the) (NN plasma) (NN membrane))))))) (PP (IN upon) (NP (CC either) (NP (NN EGF)) (CC or) (NP (NN _PROT2_) (NN stimulation)))))))) |ET|
+1 |BT| (S1 (S (NP (JJ _PROT1_) (JJ male) (NNS rats)) (VP (VBD had) (NP (NP (NP (VBN increased) (VBG circulating) (NNS levels)) (PP (IN of) (NP (NN cholecystokinin)))) (, ,) (NP (NP (DT a) (NN tendency)) (PP (TO to) (NP (NP (VBN increased) (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.066)) (-RRB- -RRB-))))))) (, ,) (CC and) (NP (NP (ADJP (RB relatively) (JJR more)) (NN adipose) (NN tissue)) (PP (IN in) (NP (DT the) (NP (NN thigh)) (CC and) (NP (JJ interscapular) (NN region)))))) (, ,) (PP (VBN compared) (PP (IN with) (NP (NNS controls))))))) |ET|
+1 |BT| (S1 (S (NP (NP (JJ _PROT1_) (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_))) (PP (IN in) (NP (JJ renal) (JJ epithelial) (NNS cells)))))) |ET|
+1 |BT| (S1 (S (NP (NN _PROT1_)) (VP (VBD induced) (NP (NP (DT a) (JJ biphasic) (NN increase)) (PP (IN in) (NP (NN diacylglycerol) (NN generation))) (, ,) (VP (VBN characterized) (PP (IN by) (NP (NP (DT an) (JJ initial) (JJ rapid) (NN rise)) (CC and) (RB then) (NP (DT a) (JJ sustained) (NN elevation)) (, ,) (CC and) (NP (NN _PROT2_) (NN activation))))) (, ,) (VP (VBN reflected) (PP (IN by) (NP (NP (NN phosphorylation)) (PP (IN of) (NP (NP (DT a) (JJ specific) (ADJP (NP (CD 80) (NN kDa)) (VBN myristoylated)) (JJ alanine-rich) (NN PKC) (NN substrate)) (PRN (-LRB- -LRB-) (NP (NN MARCKS)) (-RRB- -RRB-))))))))))) |ET|
+1 |BT| (S1 (S (NP (DT These) (NNS results)) (VP (VBP argue) (SBAR (SBAR (IN that) (S (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -dependent)) (NN _PROT1_)) (VP (VBZ is) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN action)) (PP (IN of) (NP (NN _PROT2_))))))))) (, ,) (CC and) (SBAR (IN that) (S (PP (IN of) (NP (JJ other) (NNS agonists))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP stimulate) (NP (NN sodium) (NN transport))))))))))) |ET|
-1 |BT| (S1 (S (PP (IN During) (NP (NN wk) (CD 6))) (, ,) (S (S (NP (NP (NN milk) (NN yield)) (CC and) (NP (NP (JJ dry) (NN matter) (NN intake)) (PRN (-LRB- -LRB-) (NP (NN DMI)) (-RRB- -RRB-)))) (VP (VBD were) (VP (VBN recorded) (ADVP (RB daily))))) (, ,) (CC and) (S (NP (NP (NN plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN glucose)) (, ,) (NP (JJ nonesterified) (JJ fatty) (NNS acids)) (, ,) (NP (NN urea)) (, ,) (NP (NN protein)) (, ,) (NP (NN growth) (NN hormone)) (, ,) (NP (NN _PROT1_)) (, ,) (NP (JJ insulin-like) (NN growth) (NN factor) (CD I)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN prolactin))))) (VP (VBD were) (VP (VBN determined))))))) |ET|
-1 |BT| (S1 (S (NP (NP (JJ Concurrent) (NN decrease)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NP (NN _PROT2_) (NN _PROT2_) (NN _PROT2_)) (NN immunoreactivity)))) (PP (IN during) (NP (DT the) (JJ light) (NN phase))) (PP (IN in) (NP (DT the) (JJ vole) (JJ suprachiasmatic) (NN nucleus)))))) |ET|
-1 |BT| (S1 (S (NP (NP (JJ Mean) (NNS numbers)) (PP (IN of) (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_) (NN _PROT2_))) (JJ _PROT2_) (NNS neurons)))) (VP (VBD were) (VP (VBN determined) (PP (IN in) (NP (NP (DT the) (JJ suprachiasmatic) (NN nucleus)) (PP (IN of) (NP (NP (JJ common) (NNS voles)) (, ,) (VP (VBN entrained) (PP (TO to) (NP (DT a) (ADJP (CD 12:12) (NN h)) (NN light-dark) (-LRB- -LRB-) (NN LD) (-RRB- -RRB-) (NN cycle)))))))) (, ,) (PP (IN at) (NP (NP (DT the) (NN beginning)) (PP (IN of) (NP (NP (NP (NP (DT the) (JJ light) (NN period)) (PRN (-LRB- -LRB-) (NP (NN zeitgeber) (NN time) (CD zero)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 6) (NN h)) (ADVP (RB later)))) (PRN (-LRB- -LRB-) (NP (NN zeitgeber) (NN time) (CD six)) (-RRB- -RRB-)))))))))) |ET|
-1 |BT| (S1 (S (PP (IN At) (NP (NN zeitgeber) (NN time) (CD zero))) (, ,) (NP (NP (JJ mean) (NNS numbers)) (PP (IN of) (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_) (NN _PROT2_))) (JJ _PROT2_) (JJ immunoreactive) (NNS neurons)))) (VP (VBD were) (NP (NP (CD 2194)) (CC and) (NP (CD 9897))) (, ,) (ADVP (RB respectively))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (NN distribution)) (PP (IN of) (NP (NP (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-))) (NNS cells)) (PP (IN in) (NP (DT the) (NNS SCN)))))) (VP (VBD overlapped) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NN _PROT2_))))) (PP (IN in) (NP (DT both) (NNS species)))))) |ET|
-1 |BT| (S1 (S (NP (NP (NNS Species) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NN location)) (PP (IN of) (NP (DT the) (JJ Ca2+-dependent) (NN _PROT1_) (NNS isoforms)))))) (VP (VBP suggest) (NP (NP (NP (NNS differences)) (PP (IN in) (NP (NP (NN function)) (PP (JJ such) (IN as) (NP (NP (DT the) (VBG relaying)) (PP (IN of) (NP (ADJP (ADJP (JJ photic)) (CC or) (ADJP (JJ non-photic))) (NN information))) (PP (TO to) (NP (DT the) (JJ clock) (NN mechanism)))))))) (, ,) (CC or) (NP (NP (DT the) (NN synchronization)) (PP (IN of) (NP (NN _PROT2_) (NNS neurons)))) (CC and) (NP (PRP$ their) (JJ subsequent) (NN output) (NNS signals)))))) |ET|
-1 |BT| (S1 (S (NP (DT The) (CD two) (NNS groups)) (VP (VBD were) (ADJP (JJ similar)) (PP (IN in) (NP (NP (PRP$ their) (NN morning) (NN thyroxin)) (, ,) (NP (NN triiodothyronine)) (, ,) (NP (NN TSH)) (, ,) (NP (NN estradiol) (, ,) (NN cortisol) (, ,) (NN gastrin) (, ,) (NN cholecystokinin) (, ,) (NN somatostatin) (, ,) (NN _PROT1_) (, ,) (NN _PROT2_) (CC and) (NN IGF-1) (NNS levels))))))) |ET|
+1 |BT| (S1 (S (NP (DT The) (VBN deduced) (NN consensus)) (ADVP (RB closely)) (VP (VBD resembled) (NP (NP (NN _PROT1_) (NN response) (NNS elements)) (PP (IN in) (NP (NN _PROT2_) (NNS promoters))))))) |ET|
-1 |BT| (S1 (S (S (NP (NP (NP (NN Phorbol) (NN myristate) (NN acetate)) (PRN (-LRB- -LRB-) (NP (NN TPA)) (-RRB- -RRB-))) (, ,) (NP (NP (DT an) (NN activator)) (PP (IN of) (NP (NN _PROT1_)))) (, ,)) (VP (VP (VBD elicited) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NN MAPK) (NN activity))))) (, ,) (CC but) (VP (VBD did) (RB not) (ADVP (RB further)) (VP (VB influence) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ _PROT2_) (NN MAPK) (NN activity)))))))) (: ;) (S (ADVP (RB Nevertheless)) (, ,) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NN CaMKII) (NN activation)))) (VP (VBD was) (VP (VBN attenuated) (PP (IN by) (NP (NN TPA)))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NP (DT A) (JJ neurotoxic) (NN fragment)) (PP (IN of) (NP (NN _PROT1_)))) (, ,) (NP (NP (NNP Abeta) (CD 25-35)) (, ,) (VP (VBN incubated) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (JJ endogenous) (NN Ca2+))))))) (, ,)) (VP (VBD increased) (ADVP (RB significantly)) (NP (NP (DT the) (NN _PROT2_) (NN activity)) (PP (IN of) (NP (JJ normoxic) (NN brain))))))) |ET|
+1 |BT| (S1 (S (S (PP (IN In) (NP (PRP$ its) (JJ non-aggregated) (NN form))) (, ,) (NP (NNP _PROT1_) (CD _PROT1_)) (VP (VBZ activates) (NP (NN _PROT2_)) (PP (CC but) (IN in) (NP (DT the) (VBN aggregated) (NN form))))) (S (NP (DT the) (JJ enzymatic) (NN activity)) (VP (VBD decreased))))) |ET|
+1 |BT| (S1 (S (ADVP (RB Thus)) (, ,) (NP (NN _PROT1_) (CD _PROT1_)) (VP (VP (VBZ exerts) (NP (DT a) (JJ similar) (NN effect)) (PP (IN on) (NP (NP (DT the) (JJ membrane-bound) (NN _PROT2_)) (PP (IN from) (NP (JJ normoxic) (NN brain)))))) (CC or) (VP (VBN subjected) (PP (TO to) (NP (NN ischemia) (NN reperfusion) (NN injury))))))) |ET|
+1 |BT| (S1 (S (NP (NN Ischemia-reperfusion) (NN injury)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ _PROT1_) (NNS alterations)) (PP (IN of) (NP (JJ synaptic) (NN plasma) (JJ membrane-bound) (NN _PROT2_)))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN _PROT1_) (NN beta) (NN peptide) (CD 25-35)) (VP (VBZ modulates) (NP (NP (NN hydrolysis)) (PP (IN of) (NP (NNS phosphoinositides)))) (PP (IN by) (NP (NP (NN membrane) (NN _PROT2_) (-LRB- _PROT2_) (NN _PROT2_) (-RRB- _PROT2_) (NN _PROT2_)) (PP (IN of) (NP (JJ adult) (NN brain) (NN cortex))))))))) |ET|
+1 |BT| (S1 (S (S (NP (NN Fresh-water-soluble) (NN _PROT1_) (NN _PROT1_) (CD 25-35)) (VP (VBD activated) (NP (NP (NN _PROT2_)) (PP (IN in) (NP (NN SPM)))) (ADVP (RB markedly)) (PP (IN by) (NP (CD two-) (TO to) (JJ threefold))))) (, ,) (CC but) (S (NP (DT this) (NN effect)) (VP (VBD was) (ADJP (JJ absent) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (ADJP (CD 2) (NN mM)) (NN CaCl2)))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN _PROT1_) (NN _PROT1_) (CD 25-35)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ basal) (NN _PROT2_) (NN activity)) (CC and) (NP (JJ cytosolic) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN _PROT1_) (NN _PROT1_) (CD 25-35)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ basal) (NN _PROT_) (NN activity)) (CC and) (NP (JJ cytosolic) (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN _PROT1_) (NN _PROT1_) (CD 25-35)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ basal) (NN _PROT_) (NN activity)) (CC and) (NP (JJ cytosolic) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN _PROT_) (NN _PROT_) (CD 25-35)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ basal) (NN _PROT1_) (NN activity)) (CC and) (NP (JJ cytosolic) (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN _PROT_) (NN _PROT_) (CD 25-35)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ basal) (NN _PROT1_) (NN activity)) (CC and) (NP (JJ cytosolic) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Moreover)) (, ,) (NP (NN _PROT_) (NN _PROT_) (CD 25-35)) (VP (VBD had) (NP (DT no) (NN effect)) (PP (IN on) (NP (NP (JJ basal) (NN _PROT_) (NN activity)) (CC and) (NP (JJ cytosolic) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (JJ aggregated) (NN form)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_) (CD 25-35)))) (ADVP (RB significantly)) (VP (VBD inhibited) (NP (NN _PROT2_)) (PP (ADVP (RB only)) (IN in) (DT the) (NN presence) (IN of) (NP (JJ endogenous) (NN CaCl2)))))) |ET|
+1 |BT| (S1 (S (NP (NP (JJ Hypothalamic) (NN _PROT1_) (NN _PROT1_)) (CC and) (NP (NP (PRP$ its) (JJ neuroendocrine) (NN regulation)) (PP (IN by) (NP (NN _PROT2_))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN Relationship)) (PP (IN among) (NP (NP (NP (NN _PROT1_)) (, ,) (NP (NN _PROT2_) (NN _PROT2_)) (, ,) (CC and) (NP (NN galanin))) (PP (PP (IN in) (NP (JJ young) (NNS women))) (CC and) (PP (IN in) (NP (JJ postmenopausal) (NNS women))))))) (VP (VBD [see) (NP (NNS comments))) (-RRB- -RSB-))) |ET|
-1 |BT| (S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (JJ hormonal) (NN status)) (VP (MD may) (VP (VB affect) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (, ,) (NP (NN galanin)) (, ,) (CC and) (NP (NN _PROT2_) (NN release))) (PP (PP (IN in) (NP (JJ postmenopausal) (NNS women))) (CC and) (PP (IN in) (NP (JJ young) (NNS women))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (NNS differences)) (VP (VBZ is) (NP (NP (NP (NN plasma) (NN _PROT1_)) (, ,) (NP (NN _PROT2_)) (, ,) (CC and) (NP (NN galanin))) (PP (IN between) (NP (NP (JJ postmenopausal) (NNS women)) (CC and) (NP (JJ young) (NNS women))))))) (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (PP (TO to) (NP (NN body) (NN mass) (NN index))) (CONJP (RB rather) (IN than)) (PP (TO to) (NP (NP (NNS differences)) (PP (IN in) (NP (JJ hormonal) (NN status))))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (JJR higher) (NN _PROT_) (NNS levels)) (PP (IN in) (NP (ADJP (CC both) (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (JJ postmenopausal) (NNS women))) (PP (IN than) (PP (IN in) (NP (JJ young) (NNS women))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNS factors)) (CONJP (JJ other) (IN than)) (NP (NN body) (NN mass) (NN index))) (VP (MD may) (VP (VB be) (VP (VBN involved))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (NNS differences)) (VP (VBZ is) (NP (NP (NP (NN plasma) (NN _PROT1_)) (, ,) (NP (NN _PROT_)) (, ,) (CC and) (NP (NN galanin))) (PP (IN between) (NP (NP (JJ postmenopausal) (NNS women)) (CC and) (NP (JJ young) (NNS women))))))) (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (PP (TO to) (NP (NN body) (NN mass) (NN index))) (CONJP (RB rather) (IN than)) (PP (TO to) (NP (NP (NNS differences)) (PP (IN in) (NP (JJ hormonal) (NN status))))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (JJR higher) (NN _PROT2_) (NNS levels)) (PP (IN in) (NP (ADJP (CC both) (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (JJ postmenopausal) (NNS women))) (PP (IN than) (PP (IN in) (NP (JJ young) (NNS women))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNS factors)) (CONJP (JJ other) (IN than)) (NP (NN body) (NN mass) (NN index))) (VP (MD may) (VP (VB be) (VP (VBN involved))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (SBAR (IN that) (S (NP (NP (DT the) (NNS differences)) (VP (VBZ is) (NP (NP (NP (NN plasma) (NN _PROT_)) (, ,) (NP (NN _PROT1_)) (, ,) (CC and) (NP (NN galanin))) (PP (IN between) (NP (NP (JJ postmenopausal) (NNS women)) (CC and) (NP (JJ young) (NNS women))))))) (VP (MD may) (VP (VB be) (ADJP (JJ related) (PP (PP (TO to) (NP (NN body) (NN mass) (NN index))) (CONJP (RB rather) (IN than)) (PP (TO to) (NP (NP (NNS differences)) (PP (IN in) (NP (JJ hormonal) (NN status))))))))))) (CC and) (SBAR (IN that) (S (NP (NP (DT the) (JJR higher) (NN _PROT2_) (NNS levels)) (PP (IN in) (NP (ADJP (CC both) (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (JJ postmenopausal) (NNS women))) (PP (IN than) (PP (IN in) (NP (JJ young) (NNS women))))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NNS factors)) (CONJP (JJ other) (IN than)) (NP (NN body) (NN mass) (NN index))) (VP (MD may) (VP (VB be) (VP (VBN involved))))))))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Thus)) (, ,) (S (ADVP (RB highly)) (VP (VBN expressed) (PP (IN in) (NP (JJ human) (NNS adipocytes))))) (, ,) (NP (DT the) (NN Y) (-LRB- -LRB-) (CD 1) (-RRB- -RRB-) (NN receptor)) (VP (VP (VBZ sustains) (NP (NP (DT the) (JJ strong) (JJ antilipolytic) (NN effect)) (PP (IN of) (NP (NN _PROT1_))))) (CC and) (VP (VBZ exerts) (NP (NP (DT a) (JJ positive) (NN action)) (PP (IN on) (NP (NN _PROT2_) (NN secretion)))))))) |ET|
+1 |BT| (S1 (S (SBAR (IN As) (S (VP (VBN expected) (, ,) (PP (IN in) (NP (NP (NN fusion)) (PP (IN of) (NP (NP (NP (NN _PROT1_)) (ADVP (RB alone))) (PRN (-LRB- -LRB-) (NP (CD 18) (NN microg/day)) (-RRB- -RRB-))))))))) (VP (VP (VBD augmented) (NP (NN food) (NN intake)) (PRN (-LRB- -LRB-) (NP (NP (CD 191.6) (NN %)) (PP (IN over) (NP (DT the) (JJ initial) (NN control)))) (, ,) (NP (NN P) (NN <) (CD 0.05)) (-RRB- -RRB-))) (CC and) (VP (VBD produced) (NP (DT a) (ADJP (CD 25.1) (NN %)) (NN weight) (NN gain)) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NP (DT a) (JJ 10-fold) (NN increase)) (PP (IN in) (NP (NP (NN serum) (NN _PROT2_) (NNS concentrations)) (PP (IN at) (NP (NP (DT the) (NN end)) (PP (IN of) (NP (DT the) (JJ 7-day) (NN period))))))))))))))) |ET|
+1 |BT| (S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NP (NN coinfusion)) (PP (IN of) (NP (NP (DT this) (NN regimen)) (PP (IN of) (NP (NN _PROT1_))))) (PP (IN with) (NP (NP (DT the) (ADJP (RB highly) (JJ effective)) (ADJP (ADJP (JJ anorectic)) (CC and) (ADJP (NN body) (VBG reducing))) (NNS effects)) (PP (IN of) (NP (NN CNTF)))))) (PRN (-LRB- -LRB-) (NP (CD 5.0) (NN microg/day)) (-RRB- -RRB-)) (VP (CONJP (RB not) (RB only)) (VP (VBD prevented) (NP (NP (DT the) (JJ CNTF-induced) (NN anorexia)) (CC and) (NP (NN weight) (NN loss)))) (, ,) (CONJP (CC but) (RB also)) (VP (VBN normalized) (NP (NP (NN serum) (NN _PROT2_) (NNS concentrations)) (CC and) (NP (JJ hypothalamic) (NN _PROT_) (NN gene) (NN expression))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NP (NN coinfusion)) (PP (IN of) (NP (NP (DT this) (NN regimen)) (PP (IN of) (NP (NN _PROT1_))))) (PP (IN with) (NP (NP (DT the) (ADJP (RB highly) (JJ effective)) (ADJP (ADJP (JJ anorectic)) (CC and) (ADJP (NN body) (VBG reducing))) (NNS effects)) (PP (IN of) (NP (NN CNTF)))))) (PRN (-LRB- -LRB-) (NP (CD 5.0) (NN microg/day)) (-RRB- -RRB-)) (VP (CONJP (RB not) (RB only)) (VP (VBD prevented) (NP (NP (DT the) (JJ CNTF-induced) (NN anorexia)) (CC and) (NP (NN weight) (NN loss)))) (, ,) (CONJP (CC but) (RB also)) (VP (VBN normalized) (NP (NP (NN serum) (NN _PROT_) (NNS concentrations)) (CC and) (NP (JJ hypothalamic) (NN _PROT2_) (NN gene) (NN expression))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Interestingly)) (, ,) (NP (NP (NN coinfusion)) (PP (IN of) (NP (NP (DT this) (NN regimen)) (PP (IN of) (NP (NN _PROT_))))) (PP (IN with) (NP (NP (DT the) (ADJP (RB highly) (JJ effective)) (ADJP (ADJP (JJ anorectic)) (CC and) (ADJP (NN body) (VBG reducing))) (NNS effects)) (PP (IN of) (NP (NN CNTF)))))) (PRN (-LRB- -LRB-) (NP (CD 5.0) (NN microg/day)) (-RRB- -RRB-)) (VP (CONJP (RB not) (RB only)) (VP (VBD prevented) (NP (NP (DT the) (JJ CNTF-induced) (NN anorexia)) (CC and) (NP (NN weight) (NN loss)))) (, ,) (CONJP (CC but) (RB also)) (VP (VBN normalized) (NP (NP (NN serum) (NN _PROT1_) (NNS concentrations)) (CC and) (NP (JJ hypothalamic) (NN _PROT2_) (NN gene) (NN expression))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (JJ chronic) (JJ central) (NN infusion)) (VP (TO to) (VP (VB produce) (NP (NP (DT a) (JJ persistent) (NN elevation)) (PP (IN of) (NP (DT the) (NN cytokine)))) (PP (IN at) (NP (NP (JJ pathophysiological) (NNS levels)) (PRN (-LRB- -LRB-) (NP (NP (DT a) (NN situation)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (ADVP (RB normally)) (VP (VBP manifest) (PP (IN during) (NP (NP (NN infection)) (, ,) (NP (NN injury)) (CC and) (NP (NN inflammation))))))))) (-RRB- -RRB-))))))) (VP (VBD produced) (NP (NP (NP (JJ severe) (NN anorexia)) (CC and) (NP (NN weight) (NN loss))) (PP (IN in) (NP (NP (NN conjunction)) (PP (IN with) (NP (NN reduction)))))) (PP (IN in) (NP (CC both) (NP (NN serum) (NN _PROT1_) (NNS concentrations)) (CC and) (NP (JJ hypothalamic) (NN _PROT2_) (NN gene) (NN expression)))))))))) |ET|
-1 |BT| (S1 (S (NP (DT The) (NN ARC) (NN _PROT1_) (NNS neurones)) (VP (VP (VBP are) (VP (VBN stimulated) (PP (IN by) (NP (NP (NN starvation)) (, ,) (ADVP (RB probably)) (VP (VBN mediated) (PP (IN by) (NP (NP (NNS falls)) (PP (IN in) (S (VP (VBG circulating) (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN insulin))) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (DT both) (VP (VBP inhibit) (NP (DT these) (NNS neurones)))))) (-RRB- -RRB-)))))))))))) (, ,) (CC and) (VP (VBP contribute) (PP (TO to) (NP (NP (DT the) (VBN increased) (NN hunger)) (PP (IN in) (NP (NP (DT this)) (CC and) (NP (JJ other) (NNS conditions)))) (PP (IN of) (NP (NN energy) (NN deficit))))))))) |ET|
-1 |BT| (S1 (S (NP (NN ARC) (NN _PROT1_) (NNS neurones)) (ADVP (RB also)) (VP (VBP mediate) (NP (NP (NP (NN hyperphagia)) (CC and) (NP (NN obesity))) (PP (IN in) (NP (NP (DT the) (NP (NP (NN ob/ob)) (CC and) (NP (NN db/db))) (NNS mice)) (CC and) (NP (NN fa/fa) (NN rat)))) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN _PROT2_) (NN inhibition)) (VP (VBZ is) (VP (VBN lost) (PP (IN through) (NP (NP (NNS mutations)) (VP (VBG affecting) (NP (NP (NN _PROT_)) (CC or) (NP (PRP$ its) (NN receptor)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NN ARC) (NN _PROT1_) (NNS neurones)) (ADVP (RB also)) (VP (VBP mediate) (NP (NP (NP (NN hyperphagia)) (CC and) (NP (NN obesity))) (PP (IN in) (NP (NP (DT the) (NP (NP (NN ob/ob)) (CC and) (NP (NN db/db))) (NNS mice)) (CC and) (NP (NN fa/fa) (NN rat)))) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN _PROT_) (NN inhibition)) (VP (VBZ is) (VP (VBN lost) (PP (IN through) (NP (NP (NNS mutations)) (VP (VBG affecting) (NP (NP (NN _PROT2_)) (CC or) (NP (PRP$ its) (NN receptor)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NN ARC) (NN _PROT_) (NNS neurones)) (ADVP (RB also)) (VP (VBP mediate) (NP (NP (NP (NN hyperphagia)) (CC and) (NP (NN obesity))) (PP (IN in) (NP (NP (DT the) (NP (NP (NN ob/ob)) (CC and) (NP (NN db/db))) (NNS mice)) (CC and) (NP (NN fa/fa) (NN rat)))) (, ,) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN _PROT1_) (NN inhibition)) (VP (VBZ is) (VP (VBN lost) (PP (IN through) (NP (NP (NNS mutations)) (VP (VBG affecting) (NP (NP (NN _PROT2_)) (CC or) (NP (PRP$ its) (NN receptor)))))))))))))) |ET|
-1 |BT| (S1 (S (S (NP (DT Both)) (VP (VBP receive) (NP (NP (NN information)) (PP (IN about) (NP (NP (DT the) (JJ nutritional) (NN status)) (CC and) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN energy) (NN storage))))))) (PP (IN through) (NP (NP (NP (NP (NN insulin)) (CC and) (NP (NN _PROT1_))) (NN signaling)) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ specific) (NNS receptors)) (ADJP (JJ located) (PP (IN on) (NP (NP (ADJP (ADJP (JJ POMC)) (CC and) (ADJP (JJ _PROT2_))) (NNS neurons)) (ADJP (JJ present) (PP (ADVP (RB predominantly)) (IN in) (NP (NP (DT the) (JJ arcuate) (NN nucleus)) (PRN (-LRB- -LRB-) (NP (NN ARC)) (-RRB- -RRB-))))))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (S (S (SBAR (WHADVP (WRB When)) (S (NP (NN _PROT1_) (NN signaling)) (VP (VBZ is) (ADJP (JJ defective)) (, ,) (PP (IN through) (NP (NP (DT a) (NN defect)) (PP (PP (IN in) (NP (DT either) (NP (NP (DT the) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NP (NN Zucker) (NN fa/fa) (NN rat)) (, ,) (NP (NN cp/cp) (NN rat)) (, ,) (CC and) (NP (NN db/db) (NN mouse))) (-RRB- -RRB-))))) (CC or) (PP (IN in) (NP (DT the) (NN peptide) (PRP itself))) (PRN (-LRB- -LRB-) (NP (NN ob/ob) (NN mouse)) (-RRB- -RRB-)))))))) (, ,) (NP (DT the) (NN _PROT2_) (NN system)) (VP (VBZ is) (VP (VBN upregulated) (SBAR (IN as) (S (VP (VBN shown) (PP (IN by) (NP (NP (NN mRNA) (NN overexpression)) (CC and) (NP (VBN increased) (NN peptide) (NN release)))))))))) (, ,) (IN whereas) (S (NP (NP (DT the) (NN content)) (CC and/or) (NP (NP (NN release)) (PP (IN of) (NP (NP (DT some) (JJ inhibitory) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NN neurotensin)) (, ,) (NP (NN cholecystokinin)) (-RRB- -RRB-)))))) (VP (VBP are) (VP (VBN diminished))))) (. .))) |ET|
